

# Potential consequences of the red blood cell storage lesion on cardiac electrophysiology

\*Marissa Reilly<sup>1,2</sup>, \*Chantal Bruno<sup>1,3</sup>, Tomas Prudencio<sup>1,2</sup>, Nina Ciccarelli<sup>1,2</sup>, Devon Guerrelli<sup>1,2</sup>, Raj Nair<sup>1</sup>, Manelle Ramadan<sup>1,2</sup>, Naomi L.C. Luban<sup>4,5,6</sup>, Nikki Gillum Posnack<sup>1,2,5,7</sup>

\*Authors contributed equally

Children's National Hospital, Washington DC USA 20010

<sup>1</sup> Sheikh Zayed Institute for Pediatric Surgical Innovation

<sup>2</sup> Children's National Heart Institute

<sup>3</sup> Division of Critical Care Medicine

<sup>4</sup> Division of Hematology and Laboratory Medicine

George Washington University, School of Medicine, Washington DC USA 20037

<sup>5</sup> Department of Pediatrics

<sup>6</sup> Department of Pathology

<sup>7</sup> Department of Pharmacology & Physiology

**Short Title:** Storage lesion and cardiac electrophysiology

**Corresponding author:**

Nikki Gillum Posnack, Ph.D.

Sheikh Zayed Institute, 6<sup>th</sup> floor, M7707

111 Michigan Avenue, NW

Washington, DC, USA 20010

Tel: (202) 476-2475

Email: [nposnack@childrensnational.org](mailto:nposnack@childrensnational.org)

**AUTHOR CONTRIBUTIONS:** MR<sup>1</sup>, NC, TP, CB, DG, MR<sup>2</sup>, RN performed experiments; MR<sup>1</sup>, NC, TP, DG and NGP analyzed data; MR<sup>1</sup>, NC, TP, DG and NGP prepared figures; MR<sup>1</sup>, TP, NC, CB, NL and NGP drafted manuscript; NL and NGP conceived and designed experiments; MR<sup>1</sup>, CB, NC, TP, DG, MR<sup>2</sup>, RN, NL and NGP approved manuscript. <sup>1</sup>Marissa Reilly, <sup>2</sup>Manelle Ramadan

36 **Abstract**

37 The red blood cell (RBC) storage lesion is a series of morphological, functional and metabolic  
38 changes that RBCs undergo following collection, processing and refrigerated storage for clinical  
39 use. Since the biochemical attributes of the RBC unit shifts with time, transfusion of older blood  
40 products may contribute to cardiac complications, including hyperkalemia and cardiac arrest.  
41 We measured the direct effect of storage age on cardiac electrophysiology and compared with  
42 hyperkalemia, a prominent biomarker of storage lesion severity. Donor RBCs were processed  
43 using standard blood banking techniques. The supernatant was collected from RBC units  
44 (sRBC), 7-50 days post-donor collection, for evaluation using Langendorff-heart preparations  
45 (rat) or human stem-cell derived cardiomyocytes. Cardiac parameters remained stable following  
46 exposure to 'fresh' sRBC (day 7:  $5.9 \pm 0.2$  mM  $K^+$ ), but older blood products (day 40:  $9.7 \pm 0.4$  mM  
47  $K^+$ ) caused bradycardia (baseline:  $279 \pm 5$  vs day 40:  $216 \pm 18$  BPM), delayed sinus node  
48 recovery (baseline:  $243 \pm 8$  vs day 40:  $354 \pm 23$  msec), and increased the effective refractory  
49 period of the atrioventricular node (baseline:  $77 \pm 2$  vs day 40:  $93 \pm 7$  msec) and ventricle  
50 (baseline:  $50 \pm 3$  vs day 40:  $98 \pm 10$  msec) in perfused hearts. Beating rate was also slowed in  
51 human cardiomyocytes after exposure to older sRBC ( $-75 \pm 9\%$ , day 40 vs control). Similar  
52 effects on automaticity and electrical conduction were observed with hyperkalemia (10-12 mM  
53  $K^+$ ). This is the first study to demonstrate that 'older' blood products directly impact cardiac  
54 electrophysiology, using experimental models. These effects are likely due to biochemical  
55 alterations in the sRBC that occur over time, including, but not limited to hyperkalemia. Patients  
56 receiving large volume and/or rapid transfusions may be sensitive to these effects.

57

58 **New & noteworthy**

59 We demonstrate that red blood cell storage duration time can have downstream effects on  
60 cardiac electrophysiology, likely due to biochemical alterations in the blood product.  
61 Hyperkalemia and cardiac arrest have been reported following blood transfusions, but this is the  
62 first experimental study to show a direct correlation between storage duration and cardiac  
63 function. Infant and pediatric patients, and those receiving large volume and/or rapid  
64 transfusions may be sensitive to these effects.

65 **Keywords:** red cell storage lesion, cardiac electrophysiology, hyperkalemia

66

67 **Introduction**

68 More than 13 million whole blood and red blood cell units are transfused in the United States  
69 each year, with cardiac surgical procedures accounting for ~20% of all blood transfusions(2, 10,  
70 17, 33, 34, 51, 62). Many cardiac procedures mandate the use of blood and blood products in  
71 the preoperative, intraoperative and postoperative period, particularly with infant and pediatric  
72 patients for cardiopulmonary bypass circuitry priming(38, 62). Despite the frequency, transfusion  
73 of blood and blood products are not without risk(46, 58). Transfusion of red blood cells (RBC) in  
74 particular have been associated with increased morbidity and mortality, prolongation of hospital  
75 stay, and several different cardiac complications(30, 35, 36, 42, 44, 46, 52, 58, 59). Many  
76 investigators have suggested that RBC transfusion complications are due to the transfusion of  
77 RBCs close to their expiration (42 days), wherein the effects of the red cell storage lesion can  
78 contribute to the pathobiology of adverse reactions(7, 8, 14, 26, 40, 42, 44, 53, 54, 67). These  
79 pathobiological changes include clearance of storage-damaged RBCs, aberration of nitric oxide  
80 metabolism, trapping of RBCs by macrophages resulting in oxidative damage and impaired  
81 oxygen delivery, and an increase in circulating non-transferrin bound iron(29, 48, 53, 73).  
82 Briefly, over time, stored RBCs are depleted of ATP which alters the RBC cell membrane,  
83 resulting in hemolysis, the formation of red cell microvesicles, release of intracellular iron,  
84 decreased non-transferrin bound iron and the release of free hemoglobin. Further, the pH and  
85 electrolyte composition of the RBC unit also changes due to continued anerobic metabolism and  
86 dysfunction of cation transporters. The latter includes impairment of Na<sup>+</sup>/K<sup>+</sup> ATPase(69), which  
87 leads to a progressive increase extracellular [K<sup>+</sup>] in the RBC unit supernatant(5, 28).  
88 Consequently, rapid or large volume transfusions of RBC units with elevated potassium levels  
89 can predispose patients to hyperkalemia, conduction abnormalities and cardiac arrest(7, 8, 24,  
90 42, 54, 59). Although the incidence of transfusion-associated hyperkalemia is poorly defined  
91 and potentially underreported(42), Raza, et al. noted elevated K<sup>+</sup> levels in >70% of adult trauma  
92 patients following transfusion(54), and Livingston, et al. observed hyperkalemia in 18-23% of  
93 pediatric trauma patients following transfusion(43). Transfusion-associated hyperkalemia  
94 resulting in cardiac arrest (TAHCA) is a recognized complication of massive transfusion in  
95 children, with a mean serum [K<sup>+</sup>] level of 9.2±1.8 mM in patients who experienced cardiac  
96 arrest(42). Some investigators suggest that the risk factors for TAHCA include the volume and  
97 rate of transfusion, storage age, and irradiation of RBCs – but the perceived risk and reason for  
98 such cardiac complications remains actively debated(4, 15, 28, 42).

99

## Posnack, Storage lesion and cardiac electrophysiology

100 Chronological storage age is one of the key factors that influences RBC quality and storage  
101 lesion severity(5, 12, 69). Despite this, blood banks often employ a “first-in, first-out” approach  
102 to reduce blood product waste and maintain an inventory supply to support emergency  
103 transfusions. Indeed, it is estimated that 10-20% of RBC units are transfused after 35-days of  
104 refrigerated storage, or near their 42-day expiration date(25). Some investigators have  
105 recommended a reduction in the maximum allowable storage time for RBCs due to quality  
106 concerns(29, 50, 53, 54, 61, 70, 71). Several clinical studies have raised concerns about the  
107 effects of the RBC storage lesion(8, 26, 37, 40, 42, 59, 75); however, the direct impact of RBC  
108 quality on cardiac health outcomes remains unclear. Identifying a mechanistic relationship  
109 between RBC quality and adverse cardiac endpoints has been hindered in the clinical setting by  
110 confounding factors, including disease diagnosis, age, rate/site of infusion, volume of  
111 transfusion per unit time, number of transfusions, bypass and cross-clamp time, secondary  
112 complications from surgery and concomitant medication administration. Recent randomized  
113 clinical trials have demonstrated that transfusion with fresh blood (1-10 days storage duration)  
114 does not decrease the risk of mortality compared with standard practice (2-3 weeks storage  
115 duration)(22, 27, 41, 63, 64). Although considerably less is known about the risk of transfusing  
116 RBCs near expiry (35-42 days), or the impact on secondary endpoints including cardiac  
117 complications(4, 39, 45, 55).

118 We aimed to address clinical concerns of bradycardia and cardiac arrest by investigating the  
119 direct relationship between RBC storage age and myocardial function using experimental  
120 models. We hypothesized that electrical conduction would be impaired in cardiac models  
121 exposed to the supernatant of ‘old’ RBC (sRBC) units close to expiration as compared with  
122 ‘fresh’ units, due in part to elevated extracellular potassium that can alter the myocardial resting  
123 membrane potential(3, 8, 21, 72). To test this hypothesis, electrophysiology parameters were  
124 measured using both an intact, isolated rat heart preparation and human stem-cell derived  
125 cardiomyocytes. Cardiac endpoints were measured at baseline, and again after exposure to  
126 sRBC collected from ‘fresh’ (day 7 post-donor collection), ‘old’ (day 30-40), or ‘expired’ units  
127 (day 50). We compared these results with those observed with hyperkalemia, a primary  
128 biomarker of RBC storage lesion severity(5, 12, 69).

129

### 130 **Materials and methods**

#### 131 Red blood cell sample preparation

## Posnack, Storage lesion and cardiac electrophysiology

132 Red blood cell units ( $300 \pm 50$  mL) from healthy donors were obtained from the American Red  
133 Cross or Children's National Blood Donor Center. All blood units were O-negative, sickle-  
134 negative, non-irradiated, collected using standard single donor needle methods and stored in  
135 additive preservative solution (AS-1) according to standards of the American Academy Blood  
136 Banking requirements and the Food and Drug Administration(23). Single RBC units were  
137 aliquoted into small volume blood bags typically used for neonatal transfusion; each 100 mL  
138 aliquot was stored at 4-6°C in a research-grade, temperature monitored refrigerator according to  
139 standards(23). RBC units underwent gentle centrifugation (4°C, 20 min, 3700 rpm;  
140 Haemonetics) using accumulated centrifugal effect value of  $6.5 \times 10^7$  to separate and collect the  
141 supernatant (sRBC) 7-50 days post-donor collection; sRBC samples were used for subsequent  
142 experiments. Experiments were designed to study the impact of RBC storage lesion on cardiac  
143 electrophysiology, by comparing endpoints after exposure to 'fresh' sRBC (7 days post-donor  
144 collection), 'old' sRBC (30-40 days), or 'expired' sRBC (50 days).

145

### 146 General protocol and biochemical analysis

147 Patients undergoing cardiac surgery or extracorporeal membrane oxygenation can receive large  
148 transfusion volumes equivalent to 60-70% of the patient's total blood volume(19, 47). To mimic  
149 exposure, we estimated 10% supernatant volume exposure from reconstituted blood ( $\frac{1}{2}$  volume  
150 packed RBCs [20-30% supernatant containing anticoagulant and 70-80% red blood cells] and  $\frac{1}{2}$   
151 volume plasma). Accordingly, sRBC samples were diluted to 10% volume using Krebs-  
152 Henseleit buffered media (denoted in mM: 118 NaCl, 3.29 KCl, 1.2 MgSO<sub>4</sub>, 1.12 KH<sub>2</sub>PO<sub>4</sub>, 24  
153 NaHCO<sub>3</sub>, 10 Glucose, 2 C<sub>3</sub>H<sub>3</sub>NaO<sub>3</sub>, 10 HEPES and 0.33 CaCl). Biochemical analyses were  
154 performed on each diluted sRBC sample, using an Epoc® point-of-care blood analysis system.  
155 Biochemical analyses were performed using a BGEM card (Seimens Diagnostics:  
156 SMNS10736382) to measure Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup> and lactate levels.

157

### 158 Intact, whole heart preparations

159 Animal protocols were approved by the Institutional Animal Care and Use Committee of the  
160 Children's Research Institute, and followed the National Institutes of Health's *Guide for the Care  
161 and Use of Laboratory Animals*.

162 Experiments were conducted using adult, female Sprague-Dawley rats (>8 weeks old, >200 g,  
163 Taconic Biosciences). Animals were housed in conventional rat cages in the Research Animal

## Posnack, Storage lesion and cardiac electrophysiology

164 Facility under standard environmental conditions (12:12 hour light:dark cycle, 64 – 78F, 30-70%  
165 humidity, free access to reverse osmosis water, corn cob bedding and food (2918 rodent chow,  
166 Envigo). Animals were anesthetized with 3-5% isoflurane, the heart was excised and then  
167 transferred to a temperature-controlled (37°C), constant-pressure (70 mmHg) Langendorff-  
168 perfusion system for electrophysiology experiments (**Figure 1**). After isolating and transferring  
169 the heart to the perfusion system, excised hearts were perfused with Krebs-Henseleit buffer  
170 bubbled with carbogen (95% Oxygen, 5% CO<sub>2</sub>) throughout the duration of the experiment(31).  
171 Lead II electrocardiograms (ECG) were recorded continuously during sinus rhythm; ECG  
172 signals were analyzed to quantitate heart rate, atrioventricular conduction (PR interval),  
173 ventricular depolarization time (QRS width), ventricular repolarization (QTc) and arrhythmia  
174 incidence(32, 65). Biosignals were acquired in iox2 and ECG parameters were analyzed in  
175 ecgAUTO (emka Technologies).

176

### 177 Electrophysiology measurements

178 To further investigate cardiac electrophysiology, a pacing protocol was implemented using  
179 stimulation electrodes positioned on the right atrium and the apex of the left ventricle (**Figure**  
180 **1**)(32, 65, 66). A Bloom Classic electrophysiology stimulator (Fisher Medical) was set at a  
181 pacing current 1.5x the minimum pacing threshold (1-2 mA) with 1 msec monophasic pulse  
182 width. Sinus node recovery time (SNRT) was assessed by applying a pacing train of 150 ms  
183 (S1-S1) to the right atrium and measuring the time delay until the next spontaneous sinoatrial  
184 node-mediated activity. To determine the Wenckebach cycle length (WBCL), an S1-S1 pacing  
185 interval was applied to the right atrium; the pacing cycle length was decremented stepwise to  
186 pinpoint the shortest interval that resulted in 1:1 atrioventricular conduction. Next, an S1-S2  
187 pacing interval was applied to the right atrium to determine the atrioventricular nodal effective  
188 refractory period (AVNERP). An S1-S2 pacing interval was applied to the left ventricle to find the  
189 shortest coupling interval that resulted in 1:1 ventricular depolarization, signifying the ventricular  
190 effective refractory period (VERP).

191

### 192 Experimental timeline and treatment groups

193 Isolated, intact hearts were perfused with KH media for 30 min, followed by implementation of  
194 electrophysiology pacing protocols ('baseline'). Hearts were then perfused for another 15-20  
195 min, with either KH media alone (control), media supplemented with 10% sRBC (7-50 days

## Posnack, Storage lesion and cardiac electrophysiology

196 post-donor collection), or media supplemented with elevated potassium concentrations (6-12  
197 mM KCl). Electrophysiology protocols were performed a second time to determine the effects of  
198 sRBC treatment or hyperkalemia on electrical conduction (**Figure 1**). This protocol allowed each  
199 animal to serve as its own control, and account for experimental or animal variability.

200

### 201 Human cardiomyocyte preparation and microelectrode array recordings

202 Human induced pluripotent stem cells differentiated into cardiomyocytes (hiPSC-CM; iCell  
203 cardiomyocytes) were plated onto fibronectin coated microelectrode arrays (Biocircuit MEA 24,  
204 Axion Biosystems), at a density of 30,000 cells per well. hiPSC-CM were maintained under  
205 standard cell culture conditions (37°C, 5% CO<sub>2</sub>). hiPSC-CM formed a confluent contracting  
206 monolayer 2-4 days after plating (40-60 bpm) and MEA recordings were performed 7-10 days  
207 after plating to measure the spontaneous beating rate. hiPSC-CM were equilibrated in the MEA  
208 system for 15 min, and then the spontaneous beating rate was recorded ('baseline') using an  
209 integrated microelectrode array system (Maestro Edge, Axion) with temperature and gas control  
210 (37°C, 5% CO<sub>2</sub>). Cardiomyocytes were then treated for 5 min with iCell maintenance media  
211 (control), media supplemented with 10% sRBC (7-40 days post-donor collection), or media  
212 supplemented with elevated potassium concentrations (9-12 mM). Spontaneous beating rate  
213 was also recorded 1 hr post-treatment and after washout. To account for cell plating variability,  
214 each treated cardiomyocyte monolayer was to baseline(11).

215

### 216 Data analysis

217 Results are reported as mean  $\pm$  standard error mean (n $\geq$ 3 per group). Data normality was  
218 assessed by Shapiro-Wilk testing (GraphPad Prism). A two-tailed paired t-test was performed to  
219 compare endpoints before and after treatment, within the same heart (control media or sRBC).  
220 For hyperkalemia studies with multiple doses, statistical analysis was performed using either  
221 one-way analysis of variance or Kruskal-Wallis nonparametric test, with a false discovery rate  
222 (0.1) to correct for multiple comparisons. Significance was defined as \*p<0.05.

223

## 224 **Results**

### 225 Storage age effects the biochemical composition of sRBC

226 The attributes of a stored blood product shifts as RBC quality declines, which can result in an

## Posnack, Storage lesion and cardiac electrophysiology

227 accumulation of potassium in the supernatant(5, 12, 69). To measure the effect of storage time  
228 on the electrolyte composition of blood units, sRBC samples were collected from RBC units on  
229 day 7-50 post-donor collection, samples were diluted to 10% volume using pH-buffered KH  
230 media, and then electrolyte-gas measurements were performed on the diluted end product  
231 (**Figure 2**). Extracellular potassium levels were elevated in 'old' units as compared to 'fresh'  
232 units (day 7:  $5.9 \pm 0.2$  vs day 40:  $9.7 \pm 0.4$ ,  $p < 0.0001$ ); but, there was variability between age-  
233 matched units near expiry ranging from 8.5-11.9 mM  $[K^+]$  in the 10% diluted end product (day  
234 30-50). Lactate levels were also elevated in 'old' vs 'fresh' blood units (day 7:  $0.8 \pm 0.1$  vs day 40:  
235  $2.4 \pm 0.2$  mM,  $p < 0.0001$ ).

236

### 237 Storage age is associated with heart rate slowing and sinus node dysfunction

238 Cardiac complications from RBC transfusion include an increased risk of bradycardia and  
239 cardiac arrest(42, 54, 59, 67). These adverse outcomes may be precipitated by elevated  
240 extracellular potassium, which diminishes the myocardial resting membrane potential(21, 72).  
241 Accordingly, we assessed the impact of sRBC exposure on spontaneous heart rate and sinus  
242 node function in Langendorff-perfused hearts. Heart rate remained stable throughout the study  
243 when perfused with control media containing 4.5 mM  $K^+$  (baseline:  $297 \pm 10$  msec vs 45 min:  
244  $288 \pm 15$  msec), and also remained stable when the perfusate was supplemented with 10%  
245 sRBC collected from RBC units aged 7-30 days (**Figure 3**). Similarly, sinus node function  
246 remained stable with control media perfusion (SNRT baseline:  $223 \pm 14$  vs 45 min:  $238 \pm 9$ ) and  
247 following perfusion with 10% sRBC collected from units aged 7-30 days (**Figure 3**). However, as  
248 RBC units neared expiration, sRBC exposure slowed the heart rate by 23% (baseline:  $279 \pm 5$   
249 msec vs day 40:  $216 \pm 18$  msec,  $p < 0.005$ ). Additionally, sRBC from day 40 units had a significant  
250 effect on sinus node function, delaying the recovery time by 46% (SNRT baseline:  $243 \pm 8$  msec  
251 vs day 40:  $354 \pm 23$  msec,  $p < 0.005$ ). In the latter, the perfusate media had a mean potassium  
252 concentration near 10 mM (**Figure 2**). To measure the direct effect of hyperkalemia on  
253 automaticity and sinus function, a dose-response study was performed. As the potassium  
254 concentration increased from 4.5 to 12 mM, heart rate slowed (linear regression  $R^2 = 0.92$ ,  
255  $p = 0.01$ ) and SNRT was prolonged ( $R^2 = 0.86$ ,  $p = 0.02$ ).

256

### 257 Storage age is associated with atrioventricular conduction slowing

258 Electrochemical gradients across the cardiomyocyte membrane are essential for cardiac



## Posnack, Storage lesion and cardiac electrophysiology

259 excitation and electrical propagation. Atrial cardiomyocytes are particularly sensitive to  
260 deviations in these electrochemical gradients, and an increase in extracellular potassium can  
261 slow atrioventricular (AV) conduction(18, 21, 24). Atrioventricular conduction remained constant  
262 in hearts perfused with control KH media throughout the study (**Figure 4**), as determined by  
263 ECG parameters during sinus rhythm (PR time at baseline:  $33\pm 4$  vs 45 min:  $36\pm 2$ ). Similar  
264 results were observed before and after exposure to 10% sRBC samples collected from units  
265 aged 7-30, but significant slowing was observed after exposure to sRBC near or after expiration  
266 (PR time at baseline:  $33\pm 1$  vs day 40:  $41\pm 3$  msec,  $p<0.05$ ; PR time at baseline:  $37\pm 1$  vs day 50:  
267  $53\pm 8$  msec,  $p<0.005$ ). AV node refractoriness was further interrogated by implementing an atrial  
268 pacing protocol to measure WBCL (S1-S1 pacing) and AVNERP (S1-S2 pacing). These  
269 parameters remained unchanged in hearts perfused with control media (WBCL baseline:  $79\pm 2$   
270 vs 45 min:  $83\pm 2$ ; AVNERP baseline:  $64\pm 5$  vs 45 min:  $67\pm 4$ ) and hearts exposed to sRBC from  
271 'fresh' 7-day units (**Figure 5,6**). Exposure to day 30 sRBC resulted in a modest increase in AV  
272 node refractoriness, increasing WBCL by 9%. Effects on the AV node were more pronounced  
273 after exposure to day 40 sRBC which increased AVNERP by 21% (baseline:  $77\pm 2$  vs day 40:  
274  $93\pm 7$  msec,  $p=0.01$ ) and WBCL by 19% (baseline:  $90\pm 1$  vs day 40:  $107\pm 3$ msec,  $p<0.001$ ).  
275 These effects were further exacerbated in units stored past expiration (78% increase in WBCL  
276 and 66% increase in AVNERP, baseline vs day 50 sRBC; **Figure 5,6**).

277

278 As anticipated, a dose response relationship was observed when the potassium concentration  
279 was increased in the perfusate media, resulting in prolonged atrioventricular conduction time  
280 and increased AV node refractoriness. As the potassium concentration increased from 4.5 to 12  
281 mM, a progressive increase in PR duration ( $R^2=0.85$ ,  $p<0.05$ ) was observed (**Figure 4**). At 10  
282 mM  $K^+$  (a concentration comparable to day 40 sRBC-supplemented media), a 51% increase in  
283 WBCL was observed (4.5 mM:  $84\pm 3$  to 10mM:  $127\pm 13$  msec,  $p<0.005$ ), but changes in  
284 AVNERP were only observed at 12 mM  $K^+$  (4.5 mM:  $71\pm 3$  to 12 mM:  $151\pm 21$  msec,  $p<0.005$ ;  
285 **Figure 5,6**). The latter suggests that other factors or substances in the RBC supernatant may  
286 also contribute to conduction slowing.

287

### 288 Storage age increases ventricular refractoriness

289 Severe hyperkalemia is associated with decreased sodium channel availability and slowed  
290 conduction velocity, which results in QRS widening and may precipitate ventricular

## Posnack, Storage lesion and cardiac electrophysiology

291 tachyarrhythmias(18, 21, 24). In our study model, exposure to sRBC-supplemented media did  
292 not significantly prolong the QRS duration (baseline: 26±2 msec vs day 40: 34±9 msec; **Figure**  
293 **4**), QTc duration (baseline: 169±9 vs day 40: 172±11 msec) or increase the incidence of  
294 ventricular tachyarrhythmias (data not shown). Further, we were not able to establish a trend  
295 toward QRS prolongation with increasing potassium concentration ( $R^2=0.72$ ,  $p=0.07$ ), QTc  
296 duration ( $R^2=0.67$ ,  $p=0.67$ ) or an increased incidence of ventricular tachyarrhythmias – which  
297 may be attributed to limitations in our model system. Indeed, ventricular activation and early  
298 repolarization can occur simultaneously in the rodent heart – which can influence the QRS  
299 complex and result in indistinct T-waves(6). Moreover, the rodent myocardium is less than ideal  
300 for assessing arrhythmia incidence due to its small size and resiliency to fibrillation(6). As  
301 another indicator of ventricular repolarization time, we implemented a pacing protocol to pinpoint  
302 ventricular refractoriness. A marginal increase in extracellular potassium can hasten  
303 repolarization and shorten action potential duration time – but severe hyperkalemia increases  
304 potassium channel conductance, lengthens action potential duration, and increases ventricular  
305 refractoriness(49, 72). As expected, control media perfusion resulted in stable VERP  
306 measurements throughout the study (VERP baseline: 45±5 vs 45 min: 46±2 msec). VERP  
307 measurements were unchanged in heart preparations exposed to sRBC from day 7-30 RBC  
308 units (**Figure 7**), but VERP increased by 96% following exposure to day 40 sRBC (baseline:  
309 50±3 vs day 40: 98±10 msec,  $p<0.0001$ ) and 145% after exposure to expired units (baseline:  
310 51±8 vs day 50: 126±25 msec,  $p<0.0001$ ). This increase in ventricular refractoriness may be  
311 explained, at least partly, by the increase in extracellular potassium levels. In dose response  
312 studies, increasing potassium concentration (4.5 to 12 mM) also resulted in a progressive  
313 increase in VERP (linear regression,  $R^2=0.91$ ,  $p=0.01$ ).

314

### 315 Human cardiomyocytes are susceptible to electrical disturbances

316 Rodent models are frequently employed in cardiovascular research studies, although species-  
317 specific differences in ion channel expression are established(20, 74). Accordingly, we  
318 performed a follow-up study using human cardiomyocytes (hiPSC-CM) to validate the effects of  
319 sRBC exposure. Using a microelectrode array (MEA) system, we noted an increase in the  
320 beating rate of hiPSC-CM over time when treated with day 7 sRBC (5min: 12±6% rate increase  
321  $p=0.09$  vs 60min: 33±5%  $p<0.005$ , **Figure 8**). Conversely, cardiomyocytes demonstrated  
322 bradycardia after exposure to ‘older’ sRBC products, which was more severe than reported in  
323 the whole heart experiments. The spontaneous beating rate of hiPSC-CM decreased by 47±7%

## Posnack, Storage lesion and cardiac electrophysiology

324 in day 35 samples and  $75\pm 9\%$  in day 40 samples relative to baseline measurements  
325 ( $p < 0.0001$ ). Significant slowing in the spontaneous beating rate was also observed with  
326 increasing potassium concentrations ( $4.5\text{--}12\text{ mM K}^+$ ;  $R^2 = 0.999$ ,  $p = 0.01$ ). Notably, treatment did  
327 not appear to have a lasting effect on cardiomyocyte viability, as the beating rate quickly  
328 returned to normal after washing out the sRBC or hyperkalemic media (**Figure 8**).

329

### 330 Discussion:

331 Clinical case reports have documented transfusion-associated hyperkalemia, which can lead to  
332 conduction disturbances, ventricular tachycardias, and/or cardiac arrest(3, 7, 8, 24, 42, 54, 59).  
333 Further, studies suggest that transfusion-associated adverse events may be associated with the  
334 storage age of blood products, as RBCs undergo a cascade of morphological, biochemical and  
335 metabolic changes over time that are collectively termed the 'RBC storage lesion' or 'metabolic  
336 aging'(7, 42, 54, 60). This study is the first to demonstrate that 'older' blood products may  
337 directly impact myocardial automaticity and electrical conduction, using experimental cardiac  
338 models. Importantly, we show that supernatant collected from 'fresh' RBC units (7 days post-  
339 donor collection) had no effect on heart rate, sinus node function, atrial or atrioventricular  
340 conduction, or myocardial refractoriness in an isolated, whole heart model. A follow-up study in  
341 human cardiomyocytes revealed that supplementation with 10% sRBC from 'fresh' units (day 7)  
342 had a modest increased the spontaneous beating rate over time, which may be attributed to  
343 mild hyperkalemia ( $6.0\pm 0.6\text{ mM K}^+$ ). In comparison, whole heart preparations exposed to  
344 supernatant from aged RBC units (>30 days post-collection) displayed bradycardia, slowed  
345 atrial and atrioventricular conduction, and an increase in the refractoriness of the ventricle and  
346 AV node. Notably, other groups have suggested that the maximal allowable red cell storage  
347 duration be reduced from 42 to 35 days, due to increased hemolysis and a sharp increase in  
348 nontransferrin-bound iron after 5 weeks in refrigerated storage(53). Although we did not  
349 measure either free iron or non-transferrin bound iron levels in this study, our results closely  
350 align with this conclusion, as electrophysiological disturbances were predominately observed in  
351 units stored 30+ days post-donor collection.

352

### 353 Mechanistic links between RBC transfusion and adverse cardiac outcomes

354 Blood transfusion complications include an increased risk of bradycardia and cardiac arrest,  
355 which may be precipitated by an elevated potassium level in the supernatant of RBC units(3, 8,

## Posnack, Storage lesion and cardiac electrophysiology

356 42, 59, 67). As extracellular potassium increases, electrochemical gradients are diminished and  
357 the cardiomyocyte resting membrane potential becomes less negative(18, 49, 72). Accordingly,  
358 mild hyperkalemia can enhance cardiomyocyte excitability – similar to our observation with day  
359 7 sRBC treatment in human cardiomyocytes. But, with more severe hyperkalemia, the change  
360 in resting membrane potential decreases the availability of voltage-gated sodium channels that  
361 are critical to depolarization and myocardial excitability(72). Accordingly, severe hyperkalemia is  
362 marked by sinus node dysfunction and sinus arrest(21). Similar observations were observed in  
363 our study when cardiac preparations were exposed to increasing potassium concentrations, a  
364 prominent biomarker of red cell storage lesion that can, at least in part, contribute to the  
365 electrical disturbances observed in this study.

366 As described above, hyperkalemia shifts the resting membrane potential and reduces the  
367 availability of voltage-gated sodium channels. As the action potential upstroke slows, electrical  
368 conduction slows, which manifests as a prolongation of P-waves, PR interval and QRS interval  
369 time(18, 49, 72). Atrial cardiomyocytes are the most sensitive to elevated potassium  
370 concentrations – followed by the ventricular myocardium and then specialized conductive tissue,  
371 including the sinoatrial node and bundle of His(18, 49, 72). Accordingly, electrical disturbances  
372 attributed to high  $[K^+]$  are initially observed as widened p-waves with shorter amplitudes,  
373 followed by atrioventricular and ventricular conduction delays as extracellular  $[K^+]$  continues to  
374 increase. Instead of a gradual change in cardiac parameters, we observed a global depression  
375 in electrical conduction that was largely limited to sRBC samples near expiration and/or 10-12  
376 mM  $K^+$  perfusion. The latter may be attributed to the sensitivity of our model system(6), species-  
377 specific differences in ion channel expression and electrophysiology(20, 74), and/or other  
378 attributes of the RBC storage lesion (e.g, lactate, free-iron, plasticizer leaching) that may have  
379 additional effects on cardiac electrophysiology(13, 14, 29, 32, 53).

380 Although not investigated in the present study, phthalate chemical exposure is another potential  
381 contributor to heart rate slowing and sinus node dysfunction. Phthalate chemicals are frequently  
382 used as plasticizers in blood bags, and studies have shown that storage age is associated with  
383 an accumulation of harmful phthalate chemicals in the supernatant of stored RBC products (18-  
384 fold increase, day 5 vs 42 post-donor collection)(13). Phthalate chemical exposure has been  
385 associated with bradycardia in *in vivo*(56), *in vitro*(57) and using an isolated heart model(1).  
386 Moreover, our laboratory previously reported that phthalate plasticizers can lead to sinus node  
387 dysfunction in an isolated heart model, delaying SNRT by 54% compared with control(32).  
388 Additional studies are needed to investigate the additive effects that may result from

## Posnack, Storage lesion and cardiac electrophysiology

389 hyperkalemia and phthalate chemical exposure.

390

### 391 Clinical Implications

392 In the current study, we focused our attention on hyperkalemia as a plausible mechanism for the  
393 electrophysiology disturbances observed in our model system after exposure to 'old' RBC  
394 samples. Hyperkalemia has been reported in >70% of adult trauma patients following  
395 transfusion(54), and observed in 18-23% of pediatric trauma patients following transfusion(43).  
396 Moreover, Smith, et al. reported that an increase in serum potassium levels (5.9-9.2 mEq/l) was  
397 associated with a higher risk of cardiac arrest(59), which is more likely to occur following rapid  
398 transfusion, large volume transfusion, or in cases of low cardiac output that impairs the  
399 redistribution of potassium(7, 42). Potential solutions to help mitigate the risk of hyperkalemia  
400 include prebypass filtering(16), washing RBCs(67) or limiting RBC storage duration(40, 42, 53,  
401 54, 59). Notably, longer blood storage duration has been associated with suboptimal outcomes  
402 in high-risk pediatric surgery cases(44) and cardiac operations(40, 52). Recent randomized  
403 controlled trials have indicated that transfusion of 'fresh' blood (e.g., 1-10 days) does not  
404 decrease the risk of mortality when compared to standard of care (e.g., 2-3 weeks)(22, 27, 41,  
405 63, 64). However, much less is known about the safety of prolonged RBC storage (e.g., 30-42  
406 days) or the impact of 'old' blood products on secondary cardiac endpoints(4, 55). Accordingly,  
407 expert panels have highlighted the lack of evidence-based data to reach consensus on the  
408 safety of RBC storage age in relation to critically ill children, including those undergoing surgical  
409 repair for congenital heart defects or those undergoing extracorporeal membrane  
410 oxygenation(9, 68). The presented study highlights the importance of studying the direct impact  
411 of RBC storage lesion on end-organ function, with an emphasis on cardiac electrophysiology  
412 given the sensitivity of the heart to electrolyte disturbances.

413

414 **Limitations:** The scope of our study was limited to the effects of acute cardiac exposure to  
415 supernatant collected from RBC units. Whole heart and cardiomyocyte models were used to  
416 investigate the direct effects of sRBC-mediated biochemical disturbances on electrical activity.  
417 However, *in vitro* and *ex vivo* results may differ from those observed *in vivo*, with an intact  
418 vascular and autonomic nervous system. To mimic patient exposure following a large  
419 transfusion, we estimated 10% supernatant volume exposure from reconstituted blood – based  
420 on volumes reported in cardiac surgery and/or extracorporeal membrane oxygenation studies.

## Posnack, Storage lesion and cardiac electrophysiology

421 Additional studies are warranted to assess additional effects that may result from reconstituted  
422 blood containing aged RBCs, or the risk to sensitive populations including those with low  
423 cardiac output.

424

425 **Acknowledgements:** The authors gratefully acknowledge Dr. Luther Swift for experimental  
426 technical assistance, Drs. Nobuyuki Ishibashi and Takuya Meada for assistance with electrolyte  
427 measurements, and Drs. Pranava Sinha and Charles Berul for helpful discussions. We also  
428 acknowledge Dr. Meghan Delaney and Antoine Tavares Da Souza in the Children's National  
429 Blood Bank for their assistance with procuring, storing, and collecting RBC supernatant  
430 products for this study.

431

432 **Disclosures:** Nothing to disclose.

433


434 **Funding Acknowledgements:** This work was supported by the National Institutes of Health  
435 (R01HL139472 to NGP), Sheikh Zayed Institute for Pediatric Surgical Innovation, and the  
436 Children's National Heart Institute. This publication was also supported by the Gloria and  
437 Steven Seelig family.

438

439

440

441 **FIGURES**



442 **Figure 1. Heart preparation and experimental timeline.**

443 (A) Isolated, intact rodent heart with retrograde Langendorff-perfusion via an aortic cannula.  
444 Pacing electrodes were attached to the right atria (RA) and apex of the left ventricle (LV) to  
445 perform an electrophysiology study (EP). (B) Experimental timeline included 30-min perfusion  
446 with KH-media, containing 4.5 mM K<sup>+</sup> (control), which commenced with an EP protocol.  
447 Thereafter, the media remained unchanged (control), supplemented with 10% sRBC, or  
448 supplemented with increasing potassium concentrations. The EP study was repeated again  
449 after 15-20 min, and results were compared to baseline.


450

451

## Posnack, Storage lesion and cardiac electrophysiology

452

453



454

455 **Figure 2. Biochemical composition of supernatant from red blood cell units (sRBC).**


456 Biochemical analyses of sRBC diluted to 10% volume in KH-buffered media. Storage age was  
457 associated with deviations in the electrolyte composition of sRBC samples. Mean  $\pm$  SEM, \*p < 0.05  
458 relative to control (crystalloid KH perfusion buffer), n<sub>≥</sub>3 per time point.

459

460




## Posnack, Storage lesion and cardiac electrophysiology



461 **Figure 3. RBC storage age is associated with heart rate slowing and sinus node dysfunction**

462 **(A)** Biosignals recorded from isolated hearts perfused with media supplemented with 10% sRBC  
463 collected from a day 7 unit, or **(B)** day 40 unit. Electrocardiograms were recorded during sinus  
464 rhythm (RR interval highlighted), followed by train of atrial paces (black arrows denote pacing  
465 spikes). Each atrial pace results in a ventricular response. Sinus node recovery time (SNRT) was  
466 measured from the last pacing spike to resumption of sinus rhythm. **(C)** Stable heart rate following  
467 exposure to RBC units aged 7-30 days, but bradycardia observed with sRBC collected from units  
468 aged  $\geq 40$  days. **(D)** Heart rate slowing observed at highest potassium concentration tested (12 mM  
469 K<sup>+</sup>). **(E)** Exposure to day 40 or 50 sRBC resulted in slowed sinus node recovery. **(F)** Increased  
470 SNRT also observed at highest potassium concentration tested (12 mM K<sup>+</sup>). Mean  $\pm$  SEM, \*p <  
471 0.05.

## Posnack, Storage lesion and cardiac electrophysiology




### 472 **Figure 4. RBC storage age is associated with slowed atrioventricular conduction**

473 **(A)** Electrocardiograms recorded during sinus rhythm from isolated hearts perfused with control  
474 media (left), media supplemented with 10% sRBC collected from a day 7 unit (middle) or day 40 unit  
475 (right). PR interval time is denoted. **(B)** Atrioventricular conduction slows in the presence of day 40  
476 and day 50 sRBC, or 10-12 mM K<sup>+</sup>. **(C)** Exposure to sRBC units had no measurable effect on  
477 ventricular depolarization time (QRS) during sinus rhythm. Mean  $\pm$  SEM, \*p < 0.05.

478

479


## Posnack, Storage lesion and cardiac electrophysiology



480 **Figure 5. RBC storage age is associated with increased refractoriness of the AV node**

481 **(A)** Biosignals recorded with atrial pacing (S1-S1) to measure Wenckebach cycle length (WBCL) in  
 482 isolated hearts in the presence of day 7 sRBC, **(B)** day 40 sRBC, or **(C)** 10 mM K<sup>+</sup>. **(D)** Slowed  
 483 atrioventricular node conduction following exposure to sRBC from units 30-50 days old, but not  
 484 'fresh' day 7 units. **(E)** Slowed atrioventricular conduction following exposure to 10-12 mM K<sup>+</sup>.  
 485 Arrows denote ventricular response to atrial pacing at S1 (black) pacing cycle length. ≠ denotes  
 486 failed conduction. Mean ± SEM, \*p < 0.05.


Posnack, Storage lesion and cardiac electrophysiology



487 **Figure 6. RBC storage age is associated with an increased AV node effective refractory**  
 488 **period**

489 **(A)** Biosignals recorded with atrial pacing (S1-S2) to pinpoint atrioventricular node effective  
 490 refractory period (AVNERP) in the presence of day 7 sRBC, **(B)** day 40 sRBC, or **(C)** 10 mM K<sup>+</sup>.  
 491 **(D)** AVNERP did not change after exposure to day 7-30 sRBC, but increased with day 40 and  
 492 day 50 sRBC exposure. **(E)** AVNERP increased with severe hyperkalemia. Arrows denote  
 493 ventricular response to atrial pacing at S1 (black) or S2 (gray) pacing cycle length. ≠ denotes  
 494 failed conduction. Mean ± SEM, \*p < 0.05.

Posnack, Storage lesion and cardiac electrophysiology




495 **Figure 7: RBC storage age is associated with increased ventricular refractoriness**

496 **(A)** Biosignals recorded with ventricular pacing (S1-S2) to pinpoint the ventricular effective refractory  
 497 period (VERP) in isolated hearts perfused with media supplemented with 10% sRBC collected from  
 498 a day 7 unit, **(B)** day 40 unit, or **(C)** 10 mM K<sup>+</sup>. **(D)** Ventricular refractoriness was unchanged after  
 499 exposure to day 7-30, but increased with day 40-50 sRBC and **(E)** media supplemented with 8-12  
 500 mM K<sup>+</sup>. Arrows denote ventricular response to pacing at S1 (black) or S2 (gray) pacing cycle  
 501 length. ≠ denotes failed conduction. Mean ± SD, \*p < 0.05.

Posnack, Storage lesion and cardiac electrophysiology

502



503

504 **Figure 8. Reduced automaticity in human cardiomyocytes**

505 **(A)** Microelectrode array heat map shows 16-electrode recordings from cardiomyocytes treated with  
 506 control media (4.5 mM K<sup>+</sup>), media with increasing potassium concentrations (9-12 mM K<sup>+</sup>) or 10%  
 507 sRBC collected from RBC units aged 7-40 days. The heat map corresponds to the spontaneous  
 508 beating rate. **(B)** Biosignals recorded from human cardiomyocytes show a decline in beating rate  
 509 with elevated potassium concentrations. **(C)** Percent change in beating rate following treatment with  
 510 elevated potassium concentrations, compared to baseline. **(D)** Biosignals show a decline in the  
 511 beating rate with 'older' sRBC samples (day 35-40) but not 'fresh' sRBC samples (day 7). **(E)**  
 512 Percent change in beating rate following sRBC treatment, compared with baseline. Mean  $\pm$  SEM,  
 513  $n \geq 12$ , \*Significantly different from baseline,  $p < 0.05$ .

514 REFERENCES

- 515 1. **Aronson CE, Serlick ER, Preti G.** Effects of di-2-ethylhexyl phthalate on the isolated  
516 perfused rat heart. *Toxicol Appl Pharmacol* 44: 155–169, 1978.
- 517 2. **Bateman ST, Lacroix J, Boven K, Forbes P, Barton R, Thomas NJ, Jacobs B,**  
518 **Markovitz B, Goldstein B, Hanson JH, Li HA, Randolph AG.** Anemia, Blood Loss, and  
519 Blood Transfusions in North American Children in the Intensive Care Unit. *Am J Respir*  
520 *Crit Care Med* 178: 26–33, 2008.
- 521 3. **Baz EMK, Kanazi GE, Mahfouz RAR, Obeid MY.** An unusual case of hyperkalaemia-  
522 induced cardiac arrest in a paediatric patient during transfusion of a “fresh” 6-day-old  
523 blood unit. *Transfus Med* 12: 383–6, 2002.
- 524 4. **Belpulsi D, Spitalnik S, Hod E.** The Controversy Over the Age of Blood: What Do the  
525 Clinical Trials Really Teach Us? *Blood Transfus* 15, 2017.
- 526 5. **Bennett-Guerrero E, Veldman TH, Doctor A, Telen MJ, Ortel TL, Reid TS, Mulherin**  
527 **MA, Zhu H, Buck RD, Califf RM, McMahon TJ.** Evolution of adverse changes in stored  
528 RBCs. *Proc Natl Acad Sci* 104: 17063–17068, 2007.
- 529 6. **Boukens BJ, Rivaud MR, Rentschler S, Coronel R.** Misinterpretation of the mouse  
530 ECG: “musing the waves of *Mus musculus*”. *J Physiol* 592: 4613–26, 2014.
- 531 7. **Brown KA, Bissonnette B, McIntyre B.** Hyperkalaemia during rapid blood transfusion  
532 and hypovolaemic cardiac arrest in children. *Can J Anaesth* 37: 747–754, 1990.
- 533 8. **Carvalho B, Quiney NF.** ‘Near-miss’ hyperkalaemic cardiac arrest associated with rapid  
534 blood transfusion. *Anaesthesia* 54: 1094–1096, 1999.
- 535 9. **Cholette JM, Willems A, Valentine SL, Bateman ST, Schwartz SM, Pediatric Critical**  
536 **Care Transfusion and Anemia Expertise Initiative (TAXI), Pediatric Critical Care**  
537 **Blood Research Network (BloodNet), and the Pediatric Acute Lung Injury and**  
538 **Sepsis Investigators (PALISI) Network.** Recommendations on RBC Transfusion in  
539 Infants and Children With Acquired and Congenital Heart Disease From the Pediatric  
540 Critical Care Transfusion and Anemia Expertise Initiative. *Pediatr Crit Care Med* 19:  
541 S137–S148, 2018.
- 542 10. **Chung K-W, Basavaraju S V., Mu Y, Santen KL van, Haass KA, Henry R, Berger J,**  
543 **Kuehnert MJ.** Declining blood collection and utilization in the United States. *Transfusion*  
544 56: 2184, 2016.
- 545 11. **Clements M.** Multielectrode Array (MEA) Assay for Profiling Electrophysiological Drug  
546 Effects in Human Stem Cell-Derived Cardiomyocytes. In: *Current Protocols in Toxicology*.  
547 Hoboken, NJ, USA: John Wiley & Sons, Inc., 2016, p. 22.4.1-22.4.32.
- 548 12. **D’Alessandro A, Kriebardis AG, Rinalducci S, Antonelou MH, Hansen KC,**  
549 **Papassideri IS, Zolla L.** An update on red blood cell storage lesions, as gleaned through  
550 biochemistry and omics technologies. *Transfusion* 55: 205–219, 2015.
- 551 13. **D’alessandro A, Nemkov T, Hansen KC.** Rapid detection of DEHP in packed red blood  
552 cells stored under European and US standard conditions. *Blood Transfus* 14: 140–4,  
553 2016.
- 554 14. **D’Alessandro A, Zimring JC, Busch M.** Chronological storage age and metabolic age  
555 of stored red blood cells: are they the same? *Transfusion* 59: 1620–1623, 2019.
- 556 15. **Davey RJ, McCoy NC, Yu M, Sullivan JA, Spiegel DM, Leitman SF.** The effect of

Posnack, Storage lesion and cardiac electrophysiology

- 557           prestorage irradiation on posttransfusion red cell survival. *Transfusion* 32: 525–8, 1992.
- 558   16.   **Delaney M, Axdorff-Dickey RL, Crockett GI, Falconer AL, Levario MJ, McMullan DM.**  
559       Risk of Extracorporeal Life Support Circuit-Related Hyperkalemia Is Reduced by  
560       Prebypass Ultrafiltration. *Pediatr Crit Care Med* 14: e263–e267, 2013.
- 561   17.   **Department of Health and Human Services.** *The 2011 National Blood Collection and*  
562       *Utilization Survey Report.* 2011.
- 563   18.   **Dittrich KL, Walls RM.** Hyperkalemia: ECG manifestations and clinical considerations. *J*  
564       *Emerg Med* 4: 449–455, 1986.
- 565   19.   **Durandy Y.** Blood transfusion in pediatric cardiac surgery. *Artif Organs* 34: 1057–61,  
566       2010.
- 567   20.   **Edwards AG, Louch WE.** Species-Dependent Mechanisms of Cardiac Arrhythmia: A  
568       Cellular Focus. *Clin Med Insights Cardiol* 11, 2017.
- 569   21.   **El-Sherif N, Turitto G.** Electrolyte disorders and arrhythmogenesis. *Cardiol J* 18: 233–  
570       45, 2011.
- 571   22.   **Fergusson DA, Hébert P, Hogan DL, LeBel L, Rouvinez-Bouali N, Smyth JA,**  
572       **Sankaran K, Timmouth A, Blajchman MA, Kovacs L, Lachance C, Lee S, Walker CR,**  
573       **Hutton B, Ducharme R, Balchin K, Ramsay T, Ford JC, Kakadekar A, Ramesh K,**  
574       **Shapiro S.** Effect of Fresh Red Blood Cell Transfusions on Clinical Outcomes in  
575       Premature, Very Low-Birth-Weight Infants. *JAMA* 308: 1443, 2012.
- 576   23.   **Food and Drug Administration.** *Additional standards for human blood and blood*  
577       *products.* 2020.
- 578   24.   **Friedensohn A, Faibel HE, Bairey O, Goldbourt U, Schlesinger Z.** Malignant  
579       arrhythmias in relation to values of serum potassium in patients with acute myocardial  
580       infarction. *Int J Cardiol* 32: 331–8, 1991.
- 581   25.   **Glynn SA, Klein HG, Ness PM.** The red blood cell storage lesion: the end of the  
582       beginning. *Transfusion* 56: 1462–1468, 2016.
- 583   26.   **Gruenwald CE, McCrindle BW, Crawford-Lean L, Holtby H, Parshuram C,**  
584       **Massicotte P, Van Arsdell G.** Reconstituted fresh whole blood improves clinical  
585       outcomes compared with stored component blood therapy for neonates undergoing  
586       cardiopulmonary bypass for cardiac surgery: a randomized controlled trial. *J Thorac*  
587       *Cardiovasc Surg* 136: 1442–9, 2008.
- 588   27.   **Heddle N, Cook R, Arnold D, Liu Y, Barty R, Crowther M, Devereaux P, Hirsh,**  
589       **JWarkentin T, Webert K, Roxby D, Sobieraj-Teague M, Kurz A, Sessler D, Figueroa**  
590       **P, Ellis M, Eikelboom J.** Effect of Short-Term vs. Long-Term Blood Storage on Mortality  
591       After Transfusion. *N Engl J Med* 375, 2016.
- 592   28.   **Hess J.** Red Cell Changes During Storage. *Transfus Apher Sci* 43: 51–9, 2010.
- 593   29.   **Hod EA, Spitalnik SL.** Harmful effects of transfusion of older stored red blood cells: iron  
594       and inflammation. *Transfusion* 51: 881–885, 2011.
- 595   30.   **Iyengar A, Scipione CN, Sheth P, Ohye RG, Riegger L, Bove EL, Devaney EJ,**  
596       **Hirsch-Romano JC.** Association of Complications With Blood Transfusions in Pediatric  
597       Cardiac Surgery Patients. *Ann Thorac Surg* 96: 910–916, 2013.
- 598   31.   **Jaimes III R, Kuzmiak-Glancy S, Brooks DM, Kay MW.** Short Term Functional Effects  
599       of Pyruvate Dehydrogenase Complex Activation in the Normoxic Heart. *Am J Physiol*



Posnack, Storage lesion and cardiac electrophysiology

- 600 *Hear Circ Physiol* Under Revi, 2014.
- 601 32. **Jaimes R, McCullough D, Siegel B, Swift L, McInerney D, Hiebert J, Perez-Alday E,**  
602 **Trenor B, Sheng J, Saiz J, Tereshchenko L, Posnack N.** Plasticizer Interaction With  
603 the Heart: Chemicals Used in Plastic Medical Devices Can Interfere With Cardiac  
604 Electrophysiology. *Circ. Arrhythm. Electrophysiol.* .
- 605 33. **Jonas RA.** *Comprehensive surgical management of congenital heart disease.* London:  
606 Hodder Education Group, 2004.
- 607 34. **Jones JM, Sapiano MRP, Savinkina AA, Haass KA, Baker ML, Henry RA, Berger JJ,**  
608 **Basavaraju S V.** Slowing decline in blood collection and transfusion in the United States  
609 - 2017. *Transfusion* 60 Suppl 2: S1–S9, 2020.
- 610 35. **Josephson CD, Heath Mondoro T, Ambruso DR, Sanchez R, Sloan SR, C Luban NL,**  
611 **Widness JA.** One size will never fit all: the future of research in pediatric transfusion  
612 medicine. (2014). doi: 10.1038/pr.2014.120.
- 613 36. **Karkouti K, Callum JL, Acker JP, Yip P, Rao V.** Red Cell Transfusion–Associated  
614 Hemolysis in Cardiac Surgery. *Anesth Analg* 124: 1986–1991, 2017.
- 615 37. **Keidan I, Amir G, Mandel M, Mishali D.** The metabolic effects of fresh versus old stored  
616 blood in the priming of cardiopulmonary bypass solution for pediatric patients. *J Thorac*  
617 *Cardiovasc Surg* 127: 949–952, 2004.
- 618 38. **Keung C, Smith K, Savoia H, Davidson A.** An Audit of Transfusion of Red Blood Cell  
619 Units in Pediatric Anesthesia. *Paediatr Anaesth* 19, 2009.
- 620 39. **Klein HG, Cortés-Puch I, Natanson C.** More on the Age of Transfused Red Cells. *N*  
621 *Engl J Med* 373: 283–284, 2015.
- 622 40. **Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH.**  
623 Duration of Red-Cell Storage and Complications after Cardiac Surgery. *N Engl J Med*  
624 358: 1229–1239, 2008.
- 625 41. **Lacroix J, Hébert P, Fergusson D, Tinmouth A, Cook D, Marshall J, Clayton L,**  
626 **McIntyre L, J C, Turgeon A, Blajchman M, Walsh T, Stanworth S, Campbell H,**  
627 **Capellier, GTiberghien P, Bardiaux L, van de Watering L, van der Meer N, Sabri E,**  
628 **Vo D.** Age of Transfused Blood in Critically Ill Adults. *N Engl J Med* 372, 2015.
- 629 42. **Lee AC, Reduque LL, Luban NLC, Ness PM, Anton B, Heitmiller ES.** Transfusion-  
630 associated hyperkalemic cardiac arrest in pediatric patients receiving massive  
631 transfusion. *Transfusion* 54: 244–254, 2014.
- 632 43. **Livingston MH, Singh S, Merritt NH.** Massive transfusion in paediatric and adolescent  
633 trauma patients: Incidence, patient profile, and outcomes prior to a massive transfusion  
634 protocol. *Injury* 45: 1301–1306, 2014.
- 635 44. **Manlhiot C, McCrindle BW, Menjak IB, Yoon H, Holtby HM, Brandão LR, Chan AK,**  
636 **Schwartz SM, Ben Sivarajan V, Crawford-Lean L, Foreman C, Caldarone CA, Van**  
637 **Arsdell GS, Gruenwald CE.** Longer Blood Storage Is Associated With Suboptimal  
638 Outcomes in High-Risk Pediatric Cardiac Surgery. *Ann Thorac Surg* 93: 1563–1569,  
639 2012.
- 640 45. **McQuilten ZK, Cooper DJ.** Age of Red Blood Cells for Transfusion in Critically Ill  
641 Pediatric Patients. *JAMA* 322: 2175, 2019.
- 642 46. **Murphy GJ, Reeves BC, Rogers CA, Rizvi SIA, Culliford L, Angelini GD.** Increased  
643 mortality, postoperative morbidity, and cost after red blood cell transfusion in patients

Posnack, Storage lesion and cardiac electrophysiology

- 644 having cardiac surgery. *Circulation* 116: 2544–52, 2007.
- 645 47. **Muszynski JA, Reeder RW, Hall MW, Berg RA, Shanley TP, Newth CJL, Pollack MM,**  
646 **Wessel D, Carcillo J, Harrison R, Meert KL, Dean JM, Jenkins T, Tamburro RF,**  
647 **Dalton HJ, Eunice Kennedy Shriver National Institute of Child Health and Human**  
648 **Development Collaborative Pediatric Critical Care Research Network (CPCCRN).**  
649 RBC Transfusion Practice in Pediatric Extracorporeal Membrane Oxygenation Support.  
650 *Crit Care Med* 46: e552–e559, 2018.
- 651 48. **Orlov D, Karkouti K.** The pathophysiology and consequences of red blood cell storage.  
652 *Anaesthesia* 70: 29–e12, 2015.
- 653 49. **Parham WA, Mehdirad AA, Biermann KM, Fredman CS.** Hyperkalemia revisited.  
654 *Texas Hear Inst J* 33: 40–7, 2006.
- 655 50. **Pettilä V, Westbrook AJ, Nichol AD, Bailey MJ, Wood EM, Syres G, Phillips LE,**  
656 **Street A, French C, Murray L, Orford N, Santamaria JD, Bellomo R, Cooper DJ,**  
657 **Blood Observational Study Investigators for ANZICS Clinical Trials Group.** Age of  
658 red blood cells and mortality in the critically ill. *Crit Care* 15: R116, 2011.
- 659 51. **Punjabi PP, Taylor KM.** The science and practice of cardiopulmonary bypass: From  
660 cross circulation to ECMO and SIRS. *Glob Cardiol Sci Pract* 2013: 249–60, 2013.
- 661 52. **Ranucci M, Carlucci C, Isgrò G, Boncilli A, De Benedetti D, De la Torre T, Brozzi S,**  
662 **Frigiola A.** Duration of red blood cell storage and outcomes in pediatric cardiac surgery:  
663 an association found for pump prime blood. *Crit Care* 13: R207, 2009.
- 664 53. **Rapido F, Brittenham GM, Bandyopadhyay S, La Carpia F, L’Acqua C, McMahon**  
665 **DJ, Rebbaa A, Wojczyk BS, Netterwald J, Wang H, Schwartz J, Eisenberger A,**  
666 **Soffing M, Yeh R, Divgi C, Ginzburg YZ, Shaz BH, Sheth S, Francis RO, Spitalnik**  
667 **SL, Hod EA.** Prolonged red cell storage before transfusion increases extravascular  
668 hemolysis. *J Clin Invest* 127: 375–382, 2016.
- 669 54. **Raza S, Ali Baig M, Chang C, Dabas R, Akhtar M, Khan A, Nemani K, Alani R,**  
670 **Majumder O, Gazizova N, Biswas S, Patel P, Al-Hilli JA, Shad Y, Berger BJ, Zaman**  
671 **M.** A Prospective Study on Red Blood Cell Transfusion Related Hyperkalemia in Critically  
672 Ill Patients. *J Clin Med Res* 7: 417–421, 2015.
- 673 55. **Remy KE, Spinella PC.** Red blood cell storage age – what we know from clinical trials.  
674 *Expert Rev Hematol* 9: 1011–1013, 2016.
- 675 56. **Rock G, Labow RS, Franklin C, Burnett R, Tocchi M.** Hypotension and cardiac arrest  
676 in rats after infusion of mono(2-ethylhexyl) phthalate (MEHP), a contaminant of stored  
677 blood. *N Engl J Med* 316: 1218–1219, 1987.
- 678 57. **Rubin RJ, Jaeger RJ.** Some Pharmacologic and Toxicologic Effects of Di-2-Ethylhexyl  
679 Phthalate (DEHP) and Other Plasticizers. *Environ Health Perspect* 3: 53–59, 1973.
- 680 58. **Savinkina AA, Haass KA, Sapiano MRP, Henry RA, Berger JJ, Basavaraju S V.,**  
681 **Jones JM.** Transfusion-associated adverse events and implementation of blood safety  
682 measures - findings from the 2017 National Blood Collection and Utilization Survey.  
683 *Transfusion* 60: S10–S16, 2020.
- 684 59. **Smith HM, Farrow SJ, Ackerman JD, Stubbs JR, Sprung J.** Cardiac Arrests  
685 Associated with Hyperkalemia During Red Blood Cell Transfusion: A Case Series. *Anesth*  
686 *Analg* 106: 1062–1069, 2008.
- 687 60. **Smits-Wintjens VEJ, Rath MEA, van Zwet EW, Oepkes D, Brand A, Walther FJ,**

- 688 **Lopriore E.** Neonatal Morbidity after Exchange Transfusion for Red Cell Alloimmune  
689 Hemolytic Disease. *Neonatology* 103: 141–147, 2013.
- 690 61. **Solomon SB, Wang D, Sun J, Kaniyas T, Feng J, Helms CC, Solomon MA,**  
691 **Alimchandani M, Quezado M, Gladwin MT, Kim-Shapiro DB, Klein HG, Natanson C.**  
692 Mortality increases after massive exchange transfusion with older stored blood in canines  
693 with experimental pneumonia. *Blood* 121: 1663–1672, 2013.
- 694 62. **Speiss BD.** Transfusion and outcome in heart surgery. *Ann Thorac Surg* 74: 986–7,  
695 2002.
- 696 63. **Spinella PC, Tucci M, Fergusson DA, Lacroix J, Hébert PC, Leteurtre S,**  
697 **Schechtman KB, Doctor A, Berg RA, Bockelmann T, Caro JJ, Chiusolo F, Clayton**  
698 **L, Cholette JM, Guerra GG, Josephson CD, Menon K, Muszynski JA, Nellis ME,**  
699 **Sarpal A, Schafer S, Steiner ME, Turgeon AF.** Effect of Fresh vs Standard-issue Red  
700 Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric  
701 Patients. *JAMA* 322: 2179, 2019.
- 702 64. **Steiner ME, Ness PM, Assmann SF, Triulzi DJ, Sloan SR, Delaney M, Granger S,**  
703 **Bennett-Guerrero E, Blajchman MA, Scavo V, Carson JL, Levy JH, Whitman G,**  
704 **D’Andrea P, Pulkrabek S, Ortel TL, Bornikova L, Raife T, Puca KE, Kaufman RM,**  
705 **Nuttall GA, Young PP, Youssef S, Engelman R, Greilich PE, Miles R, Josephson**  
706 **CD, Bracey A, Cooke R, McCullough J, Hunsaker R, Uhl L, McFarland JG, Park Y,**  
707 **Cushing MM, Klodell CT, Karanam R, Roberts PR, Dyke C, Hod EA, Stowell CP.**  
708 Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery. *N Engl J*  
709 *Med* 372: 1419–1429, 2015.
- 710 65. **Swift L, Jaimes R, McCullough D, Burke M, Reilly M, Maeda T, Zhang H, Ishibashi N,**  
711 **Rogers J, Posnack NG.** *Journal of visualized experiments : JoVE.* 2019.
- 712 66. **Swift LM, Burke M, Guerrelli D, Reilly M, Ramadan M, McCullough D, Prudencio T,**  
713 **Mulvany C, Chaluvadi A, Jaimes R, Posnack NG.** Age-dependent changes in  
714 electrophysiology and calcium handling: implications for pediatric cardiac research. *Am J*  
715 *Physiol Circ Physiol* 318: H354–H365, 2020.
- 716 67. **Swindell CG, Barker TA, McGuirk SP, Jones TJ, Barron DJ, Brawn WJ, Horsburgh**  
717 **A, Willetts RG.** Washing of irradiated red blood cells prevents hyperkalaemia during  
718 cardiopulmonary bypass in neonates and infants undergoing surgery for complex  
719 congenital heart disease. *Eur J Cardio-Thoracic Surg* 31: 659–664, 2007.
- 720 68. **Valentine SL, Bembea MM, Muszynski JA, Cholette JM, Doctor A, Spinella PC,**  
721 **Steiner ME, Tucci M, Hassan NE, Parker RI, Lacroix J, Argent A, Carson JL, Remy**  
722 **KE, Demaret P, Emeriaud G, Kneyber MCJ, Guzzetta N, Hall MW, Macrae D, Karam**  
723 **O, Russell RT, Stricker PA, Vogel AM, Tasker RC, Turgeon AF, Schwartz SM,**  
724 **Willems A, Josephson CD, Luban NLC, Lehmann LE, Stanworth SJ, Zantek ND,**  
725 **Bunchman TE, Cheifetz IM, Fortenberry JD, Delaney M, van de Watering L,**  
726 **Robinson KA, Malone S, Steffen KM, Bateman ST, Pediatric Critical Care**  
727 **Transfusion and Anemia Expertise Initiative (TAXI), Pediatric Critical Care Blood**  
728 **Research Network (BloodNet), and the Pediatric Acute Lung Injury and Sepsis**  
729 **Investigators (PALISI) Network.** Consensus Recommendations for RBC Transfusion  
730 Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia  
731 Expertise Initiative. *Pediatr Crit Care Med* 19: 884–898, 2018.
- 732 69. **Wallas CH.** Sodium and potassium changes in blood bank stored human erythrocytes.  
733 *Transfusion* 19: 210–5, 1979.

Posnack, Storage lesion and cardiac electrophysiology

- 734 70. **Wang D, Sun J, Solomon SB, Klein HG, Natanson C.** Transfusion of older stored blood  
735 and risk of death: a meta-analysis. *Transfusion* 52: 1184–1195, 2012.
- 736 71. **Weinberg JA, McGwin G, Griffin RL, Huynh VQ, Cherry SA, Marques MB, Reiff DA,**  
737 **Kerby JD, Rue LW.** Age of Transfused Blood: An Independent Predictor of Mortality  
738 Despite Universal Leukoreduction. *J Trauma Inj Infect Crit Care* 65: 279–284, 2008.
- 739 72. **Weiss JN, Qu Z, Shivkumar K.** Electrophysiology of Hypokalemia and Hyperkalemia.  
740 *Circ Arrhythm Electrophysiol* 10: e004667, 2017.
- 741 73. **Yoshida T, Prudent M, D'alessandro A.** Red blood cell storage lesion: causes and  
742 potential clinical consequences. *Blood Transfus* 17: 27–52, 2019.
- 743 74. **Zimmer T, Haufe V, Blechschmidt S.** Voltage-gated sodium channels in the mammalian  
744 heart. *Glob Cardiol Sci Pract* 2014: 449–63, 2014.
- 745 75. **Zubair AC.** Clinical impact of blood storage lesions. *Am J Hematol* 85: 117–22, 2010.  
746